Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

All Issues

Put It on the Board

December 2024—In a white paper released this fall, the CAP sets forth five recommendations to address private health insurers’ interference in patient-physician and physician-physician relationships by limiting the number of in-network physicians or exclusively contracting with particular providers and facilities. In the paper, “Examining the State of Health Care’s Private Payers and the Adverse Impact of Insurance Interference,” the CAP says “Two-thirds of the country’s population is covered by private health insurance, yet the coverage provided is less and less meaningful.”

Rethinking maternal AFP race adjustments

November 2024—David Grenache, PhD, D(ABCC), chief scientific officer of TriCore, is breaking no new ground when he considers the maternal serum alpha-fetoprotein test and says, “A screening test is designed to put people into one of two camps.” No scientific advances there. But the reverberations of this particular screening test have landed patients and physicians in complicated situations of late. The obvious divide is to identify increased risk of fetal abnormalities, including open neural tube defects. But the test has historically incorporated a race adjustment for Black patients. And that adjustment—seen as a way to account for reported differences in AFP values between Black and non-Black pregnant persons—in turn has come under more scrutiny recently as physicians question whether the adjustment should continue to be used, or whether it should be dropped, à la the race adjustment for eGFR/renal function. Compared with eGFR, evaluating the race adjustment in maternal serum AFP screening is more in its infancy, Dr. Grenache says.

Respiratory virus readiness, H5N1 ramp-up

November 2024—When it comes to what diseases are predicted to circulate and when, expect a respiratory virus season much like last year’s, and the year before that. As for the severity? “That’s anybody’s guess,” says Alesia McKeown, PhD, scientific partner, medical and scientific affairs at Roche Diagnostics, speaking in late September.

With eGFR in EHR, stronger clinical decision support

November 2024—In health care, information overload is hardly a novel problem. But when it comes to overlooking impaired kidney function in the electronic health record, Children’s Mercy Kansas City found a novel fix—at least for a pediatric institution. The solution, says Darcy Weidemann, MD, MHS, pediatric nephrologist at Children’s Mercy Kansas City and associate professor, University of Missouri-Kansas City School of Medicine, was to implement estimated glomerular filtration rate in the EHR.

Inside new edition of gyn cytopathology guide

November 2024—New this month from CAP Publications is the CAP Practical Guide to Gynecologic Cytopathology—Morphology, Management, and Molecular Methods, second edition. Its 15 chapters cover squamous and glandular epithelial abnormalities, anal cytology, benign changes and mimics of premalignant and malignant epithelial lesions, and much more. In this issue we provide part of the chapter on look-alikes and morphologic spectrums of change.

AMP case report: Molecular insights into the bi-clonal presence of inversion 16 and Philadelphia chromosome in relapsed post-treatment acute myeloid leukemia

November 2024—Acute myeloid leukemia (AML) stands out as the most prevalent form of leukemia, constituting 80 percent of cases in adults and 15 to 20 percent in children. It arises from the clonal proliferation of genetically aberrant hematopoietic stem and progenitor cells, impeding normal hematopoiesis. AML is linked to a variable number of cytogenetic abnormalities, and the identification of these abnormalities holds crucial implications, given their association with an elevated risk of inherited AML.

LIS experts on HL7, AI, home-test results, and more

Lab data displays, IT demands that outrun resources, at-home test results, and HL7 are some of what came up on Sept. 20 when CAP TODAY publisher Bob McGonnagle spoke online with pathologists and industry executives about laboratory information systems. “It’s fire and forget,” said Ulysses G. J. Balis, MD, of the University of Michigan, about the lack of feedback from the EHR that a clinician has seen and understood a complex result. “Loss to follow-up is a real possibility,” he said.

Surveying cancer protocol use far and wide

November 2024—Members of the CAP Foundation Global Pathology Committee and the CAP Cancer Committee collaborated to develop a three-part webinar series on how to use the CAP cancer protocols. The webinars were directed to international pathologists, particularly those in low- and middle-income countries.

MARKETPLACE

TRENDING